IP Library Patent Application 10825047
Patent Application
App. No. 10/825,047

Drug delivery via punctal plug

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/825,047
Abstract

A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

Claims (19)

1 . A method for administering an active agent to a subject, the active agent having been applied to at least one surface of an ocular implant, the method comprising installing the implant at the eye of the subject for administering the active agent through tissues of the eye.

2 . A method according to claim 1 , including the step of applying the active agent to at least one surface of the ocular implant.

3 . A method according to claim 1 , wherein the ocular implant is a punctal plug, the method including inserting the plug into a punctal aperture of the subject.

4 . A method according to claim 1 , wherein the ocular implant is a punctal plug, the method including applying the active agent to a stem of the plug and inserting the stem into a canaliculus of the subject.

5 . A method according to claim 1 , wherein the ocular implant is a punctal plug, the method including applying the active agent to a stopper of the plug, the plug having a stem for inserting into a punctal aperture of the subject.

6 . A method according to claim 1 , wherein the active agent is a medicine.

7 . A method according to claim 1 , wherein the active agent is selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.

8 . A method according to claim 1 , wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.

9 . A method according to claim 1 , wherein the implant is hollow for passing tears.

10 . A method according to claim 1 , wherein the implant is hollow for passing tears and the active agent is made available at an interior of the hollow implant for being carried by the passage of tears.

11 . An apparatus for administering an active agent to a subject, comprising an active agent applied to at least one surface of an ocular implant for installation at the eye of the subject.

12 . An apparatus according to claim 11 , wherein the ocular implant is a punctal plug.

13 . An apparatus according to claim 11 , wherein the ocular implant is a punctal plug, the active agent being on a stem of the plug for insertion into a canaliculus of the subject.

14 . An apparatus according to claim 11 , wherein the ocular implant is a punctal plug, the active agent being on a stopper of the plug, the plug having a stem for insertion into a punctal aperture of the subject.

15 . An apparatus according to claim 11 , wherein the active agent is a medicine.

16 . An apparatus according to claim 11 , wherein the active agent is selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.

17 . An apparatus according to claim 11 , wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.

18 . An apparatus according to claim 11 , wherein the implant is hollow for passing tears.

19 . An apparatus according to claim 11 , wherein the implant is hollow for passing tears and the active agent is made available at an interior of the hollow implant.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2013
From: QLT INC.
To: MATI THERAPEUTICS INC.
Reel/Frame 030266/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2011
From: 3088922, INC.
To: QLT INC.
Reel/Frame 026182/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2011
From: QLT PLUG DELIVERY, INC.
To: 3088922, INC.
Reel/Frame 026182/0792 →
CHANGE OF NAME Recorded Feb 25, 2008
From: FORSIGHT NEWCO II, INC.
To: QLT PLUG DELIVERY, INC.
Reel/Frame 020553/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2008
From: FORSIGHT LABS, LLC
To: FORSIGHT NEWCO II, INC.
Reel/Frame 020505/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2008
From: GLAZER, LIANE C
To: QLT PLUG DELIVERY, INC.
Reel/Frame 020490/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2008
From: FORSIGHT LABS, LLC
To: QLT PLUG DELIVERY, INC.
Reel/Frame 020467/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2006
From: ODRICH, STEVEN A.
To: FORSIGHT LABS, LLC
Reel/Frame 018661/0445 →